v3.25.2
Segment Information - Summary of Segment's Financial Information (Details) - USD ($)
12 Months Ended
Apr. 30, 2025
Apr. 30, 2024
Segment Reporting Information [Line Items]    
Gross Margin $ 2,470 $ 12,519
Research and development 4,386,105 2,878,554
Operations 8,355,041 6,318,289
Loss from operations (8,352,571) (6,305,770)
Interest expense 500,453 354,080
Other income (87,795) (54,642)
Total other expense 412,658 299,438
Net loss (8,765,229) (6,605,208)
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Gross Margin 2,470 12,519
Clinical and regulatory 756,189 721,428
Research and development 3,456,312 1,994,173
Sales and marketing 350,167 539,682
Operations 173,604 162,953
General and administrative 3,618,769 2,900,053
Loss from operations (8,352,571) (6,305,770)
Interest expense 500,453 354,080
Other income (87,795) (54,642)
Total other expense 412,658 299,438
Net loss $ (8,765,229) $ (6,605,208)